Seattle Genetics specializes in the production of biotechnology products, specifically anti-body based therapies and innovative technology for cancer treatment. The company also offers anti-body drug conjugates (ADCs), a specialized technology that is customized to offer targeting ability of delivery cell-killing agents into cancer cells. To address several unmet needs in the medical field, the company is creating a product pipeline that is unique and effective unlike traditional methods used in enhancing antitumor activity.
The sugar-engineered antibody technology (SEA) is a unique approach that helps to increase the potency of antibodies and this has been integrated into the ADC technology. The technology offers non-fucosylated antibodies, which result to advanced innate response to immunity. One of the main advantages of this technology is that there are no genetic modifications and standard conditions are used for cell culture. This makes the technology both simpler and cost-effective.
The SEA-CD40 antibody, which was the first to be made using the SEA technology, works through conditional activation after crosslinking. Pre-clinical studies conducted by Seattle Genetics confirmed the antibody potently stimulates immune cells that can harness patient’s immune power, which can help to fight cancer.
Clinical trials for patients
To further study the different elements of cancer treatment, Seattle Genetics conducts research through clinical trials. These trials involve people and explore new methods that can be applied in the prevention, detection, diagnosis and treatment of diseases. Clinical trials can also highlight other areas of care like improving quality of life.
Leadership: Clay B. Siegall, Ph.D.
Clay B. Siegall co-founded Seattle Genetics in 1998 and has been contributing immensely towards the development of the company. He is the President and Chief Executive Officer of the company. Clay Siegall pursued science with emphasis on cancer therapies and targeted treatments. Therefore, he built the company basing his foundation on science and innovation, reason Seattle Genetics has been creating unique healthcare solutions.
Under the leadership of Clay B. Siegall, Seattle Genetics has signed several licenses for ADC technology. These licenses include partnerships with leading companies like GlaxoSmithKline, AbbVie and Pfizer. Before joining Seattle Genetics, he worked with the Squibb Pharmaceutical Institute between the years 1991 and 1997.